Pulsipher et al. PLoS One 2021
Therapeutic Strategy
Most therapeutic strategies for oncology target key molecules involved in the late stages of disease progression and are not mechanistically based on the recent understanding of disease. As an innovative mechanism-based solution, GlycoMira’s proprietary lead asset — GM-1111 — potently inhibits innate immune receptor activation at the earliest stage of disease to mitigate further progression and ultimately result in improvements in treatment efficacy and patient outcomes.
Technology
GM-1111 Enhances Tumor Radiation Therapy
Preclinical data demonstrate that GM-1111 enhances the efficacy of radiation therapy. In the graph below, from a mouse model of human head and neck cancer, GM-1111 administration in conjunction with radiation produced a highly significant reduction in tumor volumes compared to radiation treatment alone.
GM-1111 Mitigates Oral Mucositis
In an animal model of radiation-induced oral mucositis treatment with GM-1111 significantly reduced the development of lesions of the tongue in a dose-dependent manner.
Pulsipher et al. PLoS One 2021